MicroRNA‐30d and ‐483‐3p for bi‐ventricular remodelling and miR‐126‐3p for pulmonary hypertension in advanced heart failure

Abstract

AbstractAimsMicroRNAs play a role in pathogenic mechanisms leading to heart failure. We measured a panel of 754 miRNAs in the myocardial tissue and in the serum of patients with heart failure with reduced ejection fraction due to dilatative idiopathic cardiomyopathy (DCM, N = 10) or ischaemic cardiomyopathy (N = 3), referred to left ventricular assist device implant. We aim to identify circulating miRNAs with high tissue co‐expression, significantly associated to echocardiographic and haemodynamic measures.Methods and resultsWe have measured a panel of 754 miRNAs in the myocardial tissue [left ventricular (LV) apex] and in the serum obtained at the same time in a well selected study population of end‐stage heart failure with reduced ejection fraction due to either DCM or ischaemic cardiomyopathy, referred to continuous flow left ventricular assist device implant. We observed moderate agreement for miR‐30d, miR‐126‐3p, and miR‐483‐3p. MiR‐30d was correlated to LV systolic as well as diastolic volumes (r = 0.78, P = 0.001 and r = 0.80, P = 0.005, respectively), while miR‐126‐3p was associated to mPAP and PCWP (r = −0.79, P = 0.007 and r = −0.80, P = 0.005, respectively). Finally, serum miR‐483‐3p had an association with right ventricular end diastolic diameter (r = −0.73, P = 0.02) and central venous pressure (CVP) (r − 0.68 p 0.03).ConclusionsIn patients with DCM, few miRNAs are co‐expressed in serum and tissue: They are related to LV remodelling (miR‐30d), post‐capillary pulmonary artery pressure (miR‐126‐3p), and right ventricular remodelling/filling pressures (miR‐483‐3p). Further studies are needed to confirm their role in diagnosis, prognosis or as therapeutic targets in heart failure with reduced ejection fraction.